首页> 外文期刊>The Journal of Allergy and Clinical Immunology >Intestinal dendritic cell licensing through Toll-like receptor 4 is required for oral tolerance in allergic contact dermatitis
【24h】

Intestinal dendritic cell licensing through Toll-like receptor 4 is required for oral tolerance in allergic contact dermatitis

机译:通过Toll样受体4的肠道树突式细胞许可是过敏接触皮炎中的口腔耐受性所必需的

获取原文
获取原文并翻译 | 示例
           

摘要

Background Induction of oral tolerance to haptens is an efficient way to prevent allergic contact dermatitis (ACD) in mice. Toll-like receptor (TLR)mediated sensing of the microbiota contributes to gut homeostasis, yet whether it contributes to induction of oral tolerance has not been documented. Objective We examined whether oral tolerance to the contact sensitizer 2,4-dinitro-fluorobenzene (DNFB) depends on microbiota/TLRs and evaluated the role of TLR4 on the tolerogenic function of intestinal dendritic cells (DCs). Methods Oral tolerance was induced by DNFB gavage in germ-free and mice deficient in several TLRs. Tolerance was assessed by means of suppression of contact hypersensitivity and hapten-specific IFN-?producing effector T cells. The tolerogenic function of intestinal DCs was tested by adoptive transfer experiments, ex爒ivo hapten presentation, and forkhead box p3 regulatory T-cell conversion. Results Oral tolerance induced by DNFB gavage was impaired in germ-free mice and TLR4-deficient mice. Bone marrow chimeras revealed that TLR4 expression on hematopoietic cells was necessary for oral tolerance induction. TLR4 appeared to be essential for the ability of intestinal dendritic cells from DNFB-fed mice to inhibit ACD on adoptive transfer. Indeed, TLR4 conditioned the in爒ivo mobilization to mesenteric lymph nodes of intestinal migratory CD103 + DCs carrying oral DNFB, especially the CD103 + CD11b + DC subset expressing the vitamin Aconverting enzyme retinaldehyde dehydrogenase and specialized in forkhead box p3positive regulatory T-cell conversion. Conclusions Our data demonstrate that TLR4 conditions induction of oral tolerance to DNFB through licensing tolerogenic gut DCs. Oral biotherapy with TLR4 ligands might be useful to potentiate oral tolerance to haptens and alleviate ACD in human subjects.
机译:背景技术口腔耐受性的诱导是一种有效的方法,可以防止小鼠中过敏性接触皮炎(ACD)。介导的受体(TLR)的介导的微生物群的感测有助于肠道稳态,但它是否有助于诱导口腔耐受性。目的我们研究口服耐受增敏剂2,4-二硝基氟苯(DNFB)的接触是否依赖于微生物/ Toll样受体和评估对肠道树突状细胞(DC)的耐受性功能TLR4的作用。方法DNFB Gavage在几种TLR中的无菌和小鼠中诱导口腔耐受性。通过抑制接触超敏反应和特异性IFN-α产生效应T细胞来评估耐受性。通过采用过继转移实验,EXⅣIVO HAPTEN介绍和Forkhead盒P3调节T细胞转化测试肠DC的耐受性功能。结果DNFB饲养诱导的植物耐受性在无菌小鼠和TLR4缺陷小鼠中受损。骨髓嵌合体揭示了口服耐受性诱导需要造血细胞的TLR4表达。 TLR4似乎对来自DNFB-FED小鼠的肠树突细胞能够抑制ACD在采用转移中的能力。实际上,TLR4调节in爒IVO动员肠道迁移CD103 + DC的肠道淋巴结,尤其是表达维生素射频酶转氨脱氢酶的CD103 + CD11b + DC子集,并专注于Forkhead盒P3展盒P3柱状调节T细胞转化。结论我们的数据表明,TLR4通过许可的耐受性肠道DCS诱导DNFB的口腔耐受性。口腔生物疗法与TLR4配体可能有助于使口服耐受性耐受性,并减轻人类受试者的ACD。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号